CMR Surgical said it designed Versius to be compact and modular, so it doesn’t require a dedicated OR. | Source: CMR Surgical
Stryker this week said it has invested about $400 million into CMR Surgical, with an exclusive option for it to acquire the company’s remaining equity. Stryker also secured an exclusive U.S. commercial agency agreement for the Versius portfolio.
“This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience, and global business we have built,” stated Massimiliano Colella, CEO of CMR Surgical. “Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States.”
Cambridge, U.K.-based CMR Surgical said it has designed the Versius platform for real-world operating environments. The surgical robot‘s modular architecture supports flexibility across procedures, surgeon access and sites of care, the company claimed.
CMR Surgical said that Versius can help healthcare providers grow robotic adoption within existing operating room workflows. This scalable approach can help health systems meet growing demand for robotic-assisted surgery while preserving operational flexibility and supporting long-term program economics, added the company.
Versius supports procedures including general surgery, colorectal surgery, urology, gynecology and thoracic surgery. The robot has has been adopted in hospitals across more than 30 countries and used in 45,000 cases worldwide, according to CMR.
The Versius Plus system has earned FDA 510(k) clearance for cholecystectomy. CMR has also filed a 510(k) submission for benign gynecological indications.
Source link







